News >

Neoadjuvant Immunotherapy Being Investigated in Early-Stage NSCLC

Gina Columbus @ginacolumbusonc
Published: Monday, Jan 08, 2018

Jae Y. Kim, MD

Jae Y. Kim, MD
Pivotal results from the phase III PACIFIC trial were practice-changing for patients with stage III non–small cell lung cancer (NSCLC) who received the PD-L1 inhibitor durvalumab (Imfinzi) following platinum-based chemoradiation. Now, investigators are exploring the effects of neoadjuvant immunotherapy regimens in early-stage patients.

on Advanced Non–Small Cell Lung Cancer.

OncLive: What type of data do we have thus far exploring immunotherapy in early-stage lung cancer?

Kim: So far, there have been a couple of phase II trials that have looked at CTLA-4 blockade as well as PD-1 inhibition for patients who have gone on to surgery. These have been neoadjuvant trials; the information of the trials has shown that immune checkpoint inhibition is safe for surgical patients, so the patients have gone on to surgery without major complications. For the most part, the surgery was not delayed by the immunotherapy. 
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Advances in™ Therapies for Patients With ALK-Positive Lung Cancers: More Options…More Decisions…Better OutcomesAug 30, 20191.5
Oncology Briefings™: Treating Advanced NSCLC Without Actionable MutationsAug 30, 20191.0
Publication Bottom Border
Border Publication
x